Working… Menu

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03335943
Recruitment Status : Unknown
Verified November 2017 by Wu Depei, Chinese Society of Hematology.
Recruitment status was:  Not yet recruiting
First Posted : November 8, 2017
Last Update Posted : November 8, 2017
Harbin Institute of Hematology & Oncology
Information provided by (Responsible Party):
Wu Depei, Chinese Society of Hematology

Brief Summary:
This Study aims to evaluate the efficacy and safety of CDA-2 in the treatment of International Prognostic Scoring System (IPSS) Lower/Intermediate-risk myelodysplastic syndrome (MDS) in Chinese patients.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndrome (MDS) Drug: CDA-2 (Cell Differentiation Agent 2) Phase 4

Detailed Description:

Patients with lower/intermediate-risk myelodysplastic syndrome (MDS) have rare therapeutic options other than supportive care. In pilot studies, CDA-2 showed promising results of hematological improvement in these patients.

To date, the optimal regimen for CDA-2 treatment is not well established. The researchers are going to make a multi-centered clinical trial to evaluate the efficacy and safety of CDA-2 in 800 patients with International Prognostic Scoring System(IPSS) Lower/Intermediate-risk myelodysplastic syndrome (MDS).

Eligible patients will be given CDA-2 intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles. The patients will be followed up to 24 weeks.

The primary endpoint is hematological improvement (HI) at 12 weeks according to IWG criteria. Full blood counts will be done on all patients every week. Change in bone marrow function as measured by changes in bone marrow morphology and cytogenetics will be assessed before and after 3 cycles of the treatment.

The secondary endpoint is the therapy response. Complete remission (CR), partial remission (PR) and response duration, side effects, evaluation of QOL will be evaluated at the end of the treatment in every cycle.

Adverse events of the treatment will be recorded for evaluation of the safety.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of CDA-2 for the Treatment of IPSS Lower/Intermediate-risk Myelodysplastic Syndrome Patients: a Multi-centered Prospective Open Study
Estimated Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 1, 2019
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CDA-2 (Cell Differentiation Agent 2)
Patients will be given CDA-2 therapy.
Drug: CDA-2 (Cell Differentiation Agent 2)
CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
Other Name: Uroacitides (a compound mixed of peptides and organic acids)

Primary Outcome Measures :
  1. Hematological Improvement (HI) at 12 Weeks [ Time Frame: 12 weeks ]
    Hematologic improvement (HI) per International Working Group (IWG),HI: hemoglobin increase of >= 1.5 g/dL, platelet increase of >= 30,000/mL (starting with > 20,000/mL), neutrophils increase of >= 100% and > 500/μL.

Secondary Outcome Measures :
  1. Response Rate of The Therapy at 12 Weeks [ Time Frame: 12 weeks ]
    IWG 2006 response criteria - CR: bone marrow evaluation shows <= 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin >= 11 g/dL, neutrophils >= 1000/mL, platelets >= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease >= 50%, still greater than 5% in bone marrow

  2. Red Blood Cell Transfusion Independence (RBC-TI) in 24 weeks [ Time Frame: 24 weeks ]
    Proportion of subjects who are Red blood cell (RBC) transfusion free over any consecutive 84-day period within 24 weeks

  3. Change From Baseline to that of the 24 weeks of Scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ C-30) Physical Functioning Scale [ Time Frame: 24 weeks ]
    The EORTC QLQ will be evaluated for each patients at the beginning and end of the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented diagnosis of MDS according to World Health Organization (WHO)/French American British (FAB) classification that meets IPSS-R classification of low, or intermediate-1 risk disease.
  • Subject is 18 to 85years of age the time of signing the informed consent form (ICF).
  • Able to adhere to the study visit schedule and other protocol requirements
  • Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2.
  • Laboratory test results within these ranges: Serum creatinine </=1.5 mg/dL x Upper limit of the normal (ULN),Blood urine nitrogen (BUN)</=1.5 mg/dL x Upper limit of the normal (ULN),Total bilirubin </=1.5 mg/dL x Upper limit of the normal (ULN),Serum glutamic oxaloacetic transaminase/aspartate transaminase (SGOT/AST) and Serum glutamic pyruvic transaminase/alanine transaminase (SGPT/ALT)</=2 x Upper limit of the normal (ULN).
  • No prior intensive combination chemotherapy or dose Azacitidine,Decitabine,and Lenalidomide,etc.
  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

Exclusion Criteria:

  • IPSS risk group intermediate-2 or high risk
  • breast feeding and pregnant women
  • MDS associated with del 5q cytogenetic abnormality
  • Patients with history of hepatitis B, C, HIV(+), alcoholic liver disease or evidence of hepatopathy will be excluded.
  • Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
Additional Information:
Layout table for additonal information
Responsible Party: Wu Depei, Professor, Chinese Society of Hematology Identifier: NCT03335943    
Other Study ID Numbers: CDA-2 MDS-2017
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: November 8, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wu Depei, Chinese Society of Hematology:
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions